Cyclo(-RGDfK)

• CAT Number: I002058
• CAS Number: 161552-03-0
• Molecular Formula: C27H41N9O7
• Molecular Weight: 603.7
• Purity: ≥95%
• Target: Integrin
• Solubility: DMSO: 41mg/mL
• Storage: Store at -20°C
• IUPAC Name: 2-[(2S,5R,8S,11S)-8-(4-aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid
• InChI: InChI=1S/C27H41N9O7/c28-11-5-4-9-18-24(41)34-17(10-6-12-31-27(29)30)23(40)32-15-21(37)33-20(14-22(38)39)26(43)36-19(25(42)35-18)13-16-7-2-1-3-8-16/h1-3,7-8,17-20H,4-6,9-15,28H2,(H,32,40)(H,33,37)(H,34,41)(H,35,42)(H,36,43)(H,38,39)(H4,29,30,31)/t17-,18-,19+,20-/m0/s1
• InChIKey: NVHPXYIRNJFKTE-HAGHYFMRSA-N
• SMILES: C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O

Cyclo(-RGDfK)(CAT: I002058) is a potent and selective inhibitor of the αvβ3 integrin. It belongs to the RGD (Arg-Gly-Asp) peptide family, which specifically interacts with integrins. The αvβ3 integrin is a cell surface receptor that plays a crucial role in processes such as cell adhesion, migration, and angiogenesis. By blocking the αvβ3 integrin, cyclo(-RGDfK) can inhibit these processes and has shown potential in various preclinical and clinical studies as a therapeutic agent for conditions involving angiogenesis, such as cancer and certain vascular diseases.

Reference

[1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.
[2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
[3]. Kim YS, et al. Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent. Bioorg Med Chem Lett. 2015 May 15;25(10):2056-9.